James Andrew Jamison
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by James Andrew Jamison.
Bioorganic & Medicinal Chemistry Letters | 1999
Michael J. Rodriguez; Vasu Vasudevan; James Andrew Jamison; Peter Stanley Borromeo; William Wilson Turner
A facile synthesis of phosphonate and phosphate ester prodrugs on the phenolic hydroxy of two echinocandin semisynthetic derivatives is reported. The water solubility and stability profiles of the ECB compounds varied with the choice of alkyl group used. In some cases, the ester prodrugs with small aliphatic side chains retained antifungal activity while enhancing water solubility.
Bioorganic & Medicinal Chemistry Letters | 2000
James Andrew Jamison; Stuart Levy; Xicheng Sun; Doug Zeckner; William L. Current; Mark J. Zweifel; Michael J. Rodriguez; William Wilson Turner; Shu-Hui Chen
We have described herein the syntheses of three novel series of aromatic ring containing pseudomycin side-chain analogues. Preliminary biological evaluations of these analogues clearly indicate that it is possible to synthesize rigid pseudomycin side-chain analogues without compromising in vitro antifungal activity.
Bioorganic & Medicinal Chemistry Letters | 2015
Bin Liu; Carrie H. Croy; Stephen A. Hitchcock; Jennifer R. Allen; Zhigang Rao; David A. Evans; Mark G. Bures; David L. McKinzie; Marla Watt; G. Stuart Gregory; Marvin M. Hansen; Paul J. Hoogestraat; James Andrew Jamison; Fese M. Okha-Mokube; Robert E. Stratford; William Wilson Turner; Frank P. Bymaster; Christian C. Felder
The observation that cholinergic deafferentation of circuits projecting from forebrain basal nuclei to frontal and hippocampal circuits occurs in Alzheimers disease has led to drug-targeting of muscarinic M1 receptors to alleviate cognitive symptoms. The high homology within the acetylcholine binding domain of this family however has made receptor-selective ligand development challenging. This work presents the synthesis scheme, pharmacokinetic and structure-activity-relationship study findings for M1-selective ligand, LY593093. Pharmacologically the compound acts as an orthosteric ligand. The homology modeling work presented however will illustrate that compound binding spans from the acetylcholine pocket to the extracellular loops of the receptor, a common allosteric vestibule for the muscarinic protein family. Altogether LY593093 represents a growing class of multi-topic ligands which interact with the receptors in both the ortho- and allosteric binding sites, but which exert their activation mechanism as an orthosteric ligand.
The Journal of Antibiotics | 1998
James Andrew Jamison; Lisa Marie Hammond Lagrandeur; Michael J. Rodriguez; William Wilson Turner; Douglas J. Zeckner
Archive | 1996
Peter Stanley Borromeo; James Andrew Jamison; Michael J. Rodriguez; William Wilson Turner; Venkatraghavan Vasudevan
The Journal of Antibiotics | 1997
James Andrew Jamison; Douglas J. Zeckner; Michael J. Rodriguez
Archive | 2002
Matthew David Belvo; Shu-Hui Chen; Christopher William Doecke; Sarah Lynne Hellman; James Andrew Jamison; Lawrence Edward Patterson; Michael John Rodriguez; Xicheng Sun; William Wilson Turner; Venkatraghavan Vasudevan; Mark J. Zweifel
Archive | 2000
Matthew David Belvo; Shu-Hui Chen; Christopher William Doecke; Sarah Lynne Hellman; James Andrew Jamison; Lawrence Edward Patterson; Michael John Rodriguez; Xicheng Sun; William Wilson Turner; Venkatraghavan Vasudevan; Mark J. Zweifel
Archive | 1996
Peter Stanley Borromeo; James Andrew Jamison; Michael J. Rodriguez; Turner; Venkatraghavan Vasudevan
Archive | 1996
Peter Stanley Borromeo; James Andrew Jamison; Michael J. Rodriguez; Turner; Venkatraghavan Vasudevan